Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 7

Explainer

What the Lilly and Hims GLP-1 deal means

Lilly and Hims announced a US access channel for branded obesity medicines, including Zepbound. It is a commercial deal, not a new trial.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

When Medicaid GLP-1 coverage ended

A 2026 study found a steep fall in Medicaid-reimbursed GLP-1 dispensing after five states withdrew obesity coverage.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide in HFpEF: CAMEO-SEMA MRI

A 49-person CAMEO-SEMA substudy found improved cardiac filling measures with semaglutide, without testing hospitalization or survival.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide, Depression and Motivation

A post-hoc depression-trial analysis found a change in effort-based decisions, but no proven metabolic mediator or brain mechanism.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide's Phase 3 evidence mapped

A 2026 review maps semaglutide Phase 3 trials across diabetes, obesity, cardiovascular and kidney outcomes without erasing trial limits.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide, Semaglutide and Gut Bacteria

A 36-person OMDOT-1 analysis found exploratory gut microbiome changes with tirzepatide and semaglutide, without proving a clinical benefit.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Country deep-dive

Ipamorelin status in Norway

Ipamorelin has no identified Norwegian or central EU authorisation. Here is the current status, postal-import rule, and what changed in 2026.

8 Nov 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

PT-141 personal imports into the UK

No ordinary consumer route was verified for importing PT-141 research vials. The documented UK route is licensed, notified and prescriber-led.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

What PT-141 actually costs in the UK

Zero official UK PT-141 prices were found. Here is why a specials quote, a US Vyleesi price and a research-vendor listing are different numbers.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

PT-141 UK status: what changed

No UK-authorised bremelanotide or Vyleesi product was identified. Here is the product-status boundary and the documented 12-month no-change finding.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Retatrutide personal imports into the UK

No ordinary consumer route was verified for importing Retatrutide. UK guidance requires licensed, notified and prescriber-led channels.

8 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Country deep-dive

Retatrutide UK status: what changed

Retatrutide is not authorised in the UK. MHRA warnings and seizures intensified in 2026, but no UK retail product was approved.

8 Nov 2026 · PeptideMethods Editorial Team · 6 min read